And that statement is entirely misleading.
This statement is false. The process of bringing this drug to market is long from finished ...
The process is STOPPED DEAD. The company is in default of its license obligations to Harvard and nothing is happening. At this rate it will NEVER be completed, just like every other project in the pipeline.
...and therefore has no value placed on it yet.
Wrong again. A value has been placed on the drug several times. The first time was when Lilly licensed it from Harvard over half a decade ago. That value diminished significantly when they returned the license to Harvard with a "No Thanks". Rumor has it that another pharma had it when Gabriel came along and talked Harvard into letting him try to exploit it. Each time a value has been established, currently the Harvard license is for chickenfeed (So even Harvard doesn't think they can get much for it) nevertheless DNAG doesn't think it is worth paying the license fee.
Surely if it had value to anyone else, Harvard would have retreived it by now based on DNAG's default.
No, you can't have it both ways. If it was valuable (even as a speculation) others would be competing for it. DNAG got it from someone else under similar circumstances, there is no reason to doubt that anyone with the necessary liquidity could not take it away.
The absolute lack of interest by the industry AND the market, is VALIDATION of its lack of value.
The patent issue is of utmost significance. Please don't attempt to brush it off with nothing more than snide comments. AMGEN has successfully defended their ownership of the EPO molecule. PT-401 uses that molecule. There is no wiggle room following the latest court rulings. You can try all you want to repeat old PRs but DNAGs refusal to pay the license fees is quite telling don't you think? Even they are not willing to throw money away......not when they could use it to grant themselves a bonus or pay for a trip to Europe.
regards,
frog
News 
Market Data 
Discover 
AI
